Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Simulations Plus ( (SLP) ).
Simulations Plus, Inc. announced the rescheduling of its third quarter fiscal 2025 earnings release and conference call, initially set for July 2, 2025, now moved to July 14, 2025. This adjustment follows the company’s transition from a large accelerated filer to a non-accelerated filer, allowing it to use the full regulatory time for releasing financial results. The company reaffirmed its preliminary third quarter revenue estimates of $19 to $20 million and full-year 2025 revenue guidance of $76 to $80 million. These figures are preliminary and subject to adjustments in the final financial statements.
The most recent analyst rating on (SLP) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Simulations Plus stock, see the SLP Stock Forecast page.
Spark’s Take on SLP Stock
According to Spark, TipRanks’ AI Analyst, SLP is a Neutral.
Simulations Plus’s strong financial performance and positive earnings call sentiment support a favorable outlook, despite technical analysis indicating bearish momentum and valuation concerns with a high P/E ratio. The reaffirmed guidance and revenue growth provide confidence, although challenges in project initiation and gross margins could pose headwinds.
To see Spark’s full report on SLP stock, click here.
More about Simulations Plus
Simulations Plus, Inc. is a leading provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company integrates artificial intelligence/machine learning, physiologically based pharmacokinetics, and other modeling approaches to deliver simulation-enabled performance and intelligence solutions, as well as medical communications support for clinical and commercial drug development. Its technology is utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
Average Trading Volume: 389,487
Technical Sentiment Signal: Sell
Current Market Cap: $381.1M
Find detailed analytics on SLP stock on TipRanks’ Stock Analysis page.